Abstract A096: PIKfyve as a potential therapeutic target in pancreatic cancer
Shea Grenier,Cheska Galapate,Yijuan Zhang,Gurpreet Arora,Steven Olson,Brooke Emerling,Cosimo Commisso
DOI: https://doi.org/10.1158/1538-7445.panca2023-a096
IF: 11.2
2024-01-16
Cancer Research
Abstract:Abstract A lack of effective treatments beyond surgical resection and chemotherapy contributes to the 12% five-year survival rate of pancreatic ductal adenocarcinoma (PDAC), underscoring the need to identify novel therapeutic approaches. Pharmacological inhibition of phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) with small molecules has been demonstrated to have therapeutic effects in tauopathies, viral infection, and cancer; however, these compounds have not been evaluated in PDAC. The PIKfyve lipid kinase generates PI5P and/or PI(3,5)P2 from phosphoinositol (PI) or PI3P, respectively, and is associated with cellular signaling, membrane homeostasis, and vesicular trafficking. Evidence suggests that PIKfyve inhibitors exhibit anti-cancer effects through autophagy inhibition and lysosomal impairment in non-Hodgkin’s B cell lymphoma, multiple myeloma, and prostate cancer, among other cancer types. Here, we report that the treatment of PDAC cells with apilimod, a PIKfyve-specific inhibitor, results in increased cytoplasmic vacuolization, a characteristic phenotype, increased expression of transcription factor EB (TFEB), and antiproliferative effects in vitro. We also demonstrate that apilimod is a novel inhibitor of macropinocytosis, an endocytic mechanism of nutrient uptake in PDAC. YM201636, another PIKfyve inhibitor, exhibits similar vacuolization and cytostatic effects in PDAC cells. Importantly, preliminary data suggests that genetic knockdown of PIKfyve phenocopies the observed pharmacological effects in vitro. Future experiments will assess the mechanistic underpinnings of PIKfyve function using agonists and endosomal inhibitors and will investigate the in vivo therapeutic potential of targeting PIKfyve in PDAC. Combined, this study will assess PIKfyve as a potential target in the treatment of PDAC for which novel therapeutics are urgently needed. Citation Format: Shea Grenier, Cheska Galapate, Yijuan Zhang, Gurpreet Arora, Steven Olson, Brooke Emerling, Cosimo Commisso. PIKfyve as a potential therapeutic target in pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl):Abstract nr A096.
oncology